Premium
O1‐04‐06: Effects of rosiglitazone as monotherapy in APOE4‐stratified subjects with mild‐to‐moderate Alzheimer's disease
Author(s) -
Gold Michael,
Alderton Claire,
ZvartauHind Marina,
Ritchie Sally,
Saunders Ann,
Craft Suzanne,
Landreth Gary,
Sawchak Sharon
Publication year - 2009
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2009.05.219
Subject(s) - placebo , medicine , tolerability , population , donepezil , apolipoprotein e , psychology , dementia , disease , adverse effect , pathology , alternative medicine , environmental health
O1-04-06 EFFECTS OF ROSIGLITAZONE AS MONOTHERAPY IN APOE4-STRATIFIED SUBJECTS WITH MILD-TO-MODERATE ALZHEIMER’S DISEASE Michael Gold, Claire Alderton, Marina Zvartau-Hind, Sally Ritchie, Ann Saunders, Suzanne Craft, Gary Landreth, Ülla Linnamägi, Sharon Sawchak, GlaxoSmithKline, Durham, NC, USA; GlaxoSmithKline, Greenford, United Kingdom; GlaxoSmithKline, Harlow, United Kingdom; University of Washington School of Medicine, Seattle, WA, USA; Case Western Reserve University School of Medicine, Cleveland, OH, USA; University of Tartu, Tartu, Estonia. Contact e-mail: cheryl.baker@ envisionpharma.com